Clinical review about TRAb assay's history.
Commercial assays to measure thyroid stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAb) have been available for the serological diagnosis of autoimmune thyroid diseases (AITD) for several years. The widespread assessment of this parameter has identified Graves' disease (GD) as a common organ-specific autoimmune disease. Within the present article we aim to review immunobiological and epidemiological aspects as well as diagnostic methods available for the detection of TRAb. Over the last decade, TRAb detection in GD became more sensitive since TRAb assays were being largely improved by named research groups. Therefore, functional assay (fas) and diagnostic sensitivity of current TRAb assays will be discussed. Within the second part of this review we will focus on clinical applications of TRAb measurement for outcome prediction of GD as well as the importance of this method to distinguish GD from other AITD.
Zöphel
Klaus
K
Department of Nuclear Medicine, University of Technology Dresden, Germany. klaus.zoephel@uniklinikum-dresden.de
Roggenbuck
Dirk
D
Schott
Matthias
M
D000911:Antibodies, Monoclonal; D001323:Autoantibodies / Q000097:blood; D003937:Diagnosis, Differential; D006111:Graves Disease / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D009928:Organ Specificity; D011379:Prognosis; D011989:Receptors, Thyrotropin / Q000276:immunology*; D012698:Serologic Tests / Q000379:methods; D013967:Thyroiditis, Autoimmune / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D011989:Receptors, Thyrotropin